Cell of Origin for Malignant Gliomas and Its Implication in Therapeutic Development
Cell of Origin for Malignant Gliomas and Its Implication in Therapeutic Development
复制标题
DOI：
10.1101/cshperspect.a020610
复制
发表时间：
2015-05-01
影响因子：
7.2
通讯作者：
Baker, Suzanne J.
中科院分区：
文献类型：
--
作者：
Zong, Hui;Parada, Luis F.;Baker, Suzanne J.
尽管基础研究和临床实践取得了巨大进步，恶性神经胶质瘤仍然无法治愈。对起源细胞的识别应该可以深入了解阻止疾病进展的杠杆点。在这里，我们总结了最近的研究，这些研究支持神经干细胞（NSC）、星形胶质细胞和少突胶质细胞前体细胞（OPC）都可以作为起源细胞的观点。我们还为进一步探索这一主题提出了关于技术严谨性的重要考虑因素。最后，我们分享了如何应用细胞起源知识来开发有效治疗方法的观点。尽管这将是一场艰苦的战斗，但只要我们继续吸收新信息并促进基础科学家、转化研究人员和临床医生之间的合作，胜利就应该是指日可待的。
Malignant glioma remains incurable despite tremendous advancement in basic research and clinical practice. The identification of the cell(s) of origin should provide deep insights into leverage points for one to halt disease progression. Here we summarize recent studies that support the notion that neural stem cell (NSC), astrocyte, and oligodendrocyte precursor cell (OPC) can all serve as the cell of origin. We also lay out important considerations on technical rigor for further exploring this subject. Finally, we share perspectives on howone could apply the knowledge of cell of origin to develop effective treatment methods. Although it will be a difficult battle, victory should be within reach as along as we continue to assimilate new information and facilitate the collaboration among basic scientists, translational researchers, and clinicians.